MAM
DFTX

Meeder Asset Management’s Definium Therapeutics DFTX Stock Holding History

Meeder Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-353
Closed -$6.67K – 1006
2026
Q1 		$6.67K Buy
+353
New +$5.99K ﹤0.01% 780
2021
Q4 		– Sell
-140
Closed -$4K – 1876
2021
Q3 		$4K Buy
+140
New +$6.05K ﹤0.01% 2011

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Meeder Asset Management's DFTX Position: Q2 2026 in Review

Meeder Asset Management sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 353 shares — an estimated $6.67K sold.

Meeder Asset Management first reported a position in DFTX in Q3 2021 and held it in 2 quarters. The position peaked at $6.67K in Q1 2026. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Meeder Asset Management reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Meeder Asset Management sold 353 Definium Therapeutics shares in Q2 2026, an estimated $6.67K.
  • Meeder Asset Management first reported a position in Definium Therapeutics in Q3 2021 and held it in 2 quarters.
  • Meeder Asset Management's Definium Therapeutics position peaked at $6.67K in Q1 2026.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.